ProPhase Labs, Inc. Investment Income, Interest
ProPhase Labs, Inc. (PRPH) reported Investment Income, Interest of $153.00 thousand for the 12-month period ending 2022-12-31, per its 10-K filed 2023-03-29.
Discontinued › Income Statement › Other Income
us-gaap:InvestmentIncomeInterest · last filed 2023-03-29
- ProPhase Labs, Inc. investment income, interest for the quarter ending 2021-12-31 was $111.00K, a 1133.33% increase year-over-year.
- ProPhase Labs, Inc. investment income, interest for the quarter ending 2021-09-30 was $230.00K, a 489.74% increase year-over-year.
- ProPhase Labs, Inc. investment income, interest for the quarter ending 2021-06-30 was $214.00K, a 1845.45% increase year-over-year.
- ProPhase Labs, Inc. investment income, interest for the quarter ending 2021-03-31 was $87.00K, a 2800.00% increase year-over-year.
- ProPhase Labs, Inc. investment income, interest for fiscal 2022 was $153.00K, a 76.17% decline from fiscal 2021.
- ProPhase Labs, Inc. investment income, interest for fiscal 2021 was $642.00K, a 935.48% increase from fiscal 2020.
- ProPhase Labs, Inc. investment income, interest for fiscal 2020 was $62.00K, a 53.38% decline from fiscal 2019.
- ProPhase Labs, Inc. investment income, interest for fiscal 2019 was $133.00K, a 20.36% decline from fiscal 2018.
| Period end | Investment Income, Interest 3 month | Investment Income, Interest 6 month | Investment Income, Interest 9 month | Investment Income, Interest 12 month |
|---|---|---|---|---|
| 2022-12-31 | $153.00K 10-K · filed 2023-03-29 | |||
| 2021-12-31 | $111.00K derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-29 | $341.00K derived: sum of 2 quarters · filed 2023-03-29 | $555.00K derived: sum of 3 quarters · filed 2023-03-29 | $642.00K 10-K · filed 2023-03-29 |
| 2021-09-30 | $230.00K 10-Q · filed 2021-11-12 | $444.00K derived: sum of 2 quarters · filed 2021-11-12 | $531.00K 10-Q · filed 2021-11-12 | $540.00K derived: sum of 4 quarters · filed 2022-03-31 |
| 2021-06-30 | $214.00K 10-Q · filed 2021-08-13 | $301.00K 10-Q · filed 2021-08-13 | $310.00K derived: sum of 3 quarters · filed 2022-03-31 | $349.00K derived: sum of 4 quarters · filed 2022-03-31 |
| 2021-03-31 | $87.00K 10-Q · filed 2021-05-14 | $96.00K derived: sum of 2 quarters · filed 2022-03-31 | $135.00K derived: sum of 3 quarters · filed 2022-03-31 | $146.00K derived: sum of 4 quarters · filed 2022-03-31 |
| 2020-12-31 | $9.00K derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-31 | $48.00K derived: sum of 2 quarters · filed 2022-03-31 | $59.00K derived: sum of 3 quarters · filed 2022-03-31 | $62.00K 10-K · filed 2022-03-31 |
| 2020-09-30 | $39.00K 10-Q · filed 2021-11-12 | $50.00K derived: sum of 2 quarters · filed 2021-11-12 | $53.00K 10-Q · filed 2021-11-12 | $92.00K derived: sum of 4 quarters · filed 2021-11-12 |
| 2020-06-30 | $11.00K 10-Q · filed 2021-08-13 | $14.00K 10-Q · filed 2021-08-13 | $53.00K derived: sum of 3 quarters · filed 2021-08-13 | $86.00K derived: sum of 4 quarters · filed 2021-08-13 |
| 2020-03-31 | $3.00K 10-Q · filed 2021-05-14 | $42.00K derived: sum of 2 quarters · filed 2021-05-14 | $75.00K derived: sum of 3 quarters · filed 2021-05-14 | $105.00K derived: sum of 4 quarters · filed 2021-05-14 |
| 2019-12-31 | $39.00K derived: 10-K 12 month − 10-Q 9 month · filed 2021-03-31 | $72.00K derived: sum of 2 quarters · filed 2021-03-31 | $102.00K derived: sum of 3 quarters · filed 2021-03-31 | $133.00K 10-K · filed 2021-03-31 |
| 2019-09-30 | $33.00K 10-Q · filed 2020-11-19 | $63.00K derived: sum of 2 quarters · filed 2020-11-19 | $94.00K 10-Q · filed 2020-11-19 | $146.00K derived: sum of 4 quarters · filed 2020-11-19 |
| 2019-06-30 | $30.00K 10-Q · filed 2020-08-11 | $61.00K 10-Q · filed 2020-08-11 | $113.00K derived: sum of 3 quarters · filed 2020-08-11 | $128.00K derived: sum of 4 quarters · filed 2020-08-11 |
| 2019-03-31 | $31.00K 10-Q · filed 2020-05-12 | $83.00K derived: sum of 2 quarters · filed 2020-05-12 | $98.00K derived: sum of 3 quarters · filed 2020-05-12 | $103.00K derived: sum of 4 quarters · filed 2020-05-12 |
| 2018-12-31 | $52.00K derived: 10-K 12 month − 10-Q 9 month · filed 2020-03-26 | $67.00K derived: sum of 2 quarters · filed 2020-03-26 | $72.00K derived: sum of 3 quarters · filed 2020-03-26 | $167.00K 10-K · filed 2020-03-26 |
| 2018-09-30 | $15.00K 10-Q · filed 2019-11-12 | $20.00K derived: sum of 2 quarters · filed 2019-11-12 | $115.00K 10-Q · filed 2019-11-12 | |
| 2018-06-30 | $5.00K 10-Q · filed 2019-08-12 | $100.00K 10-Q · filed 2019-08-12 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Xenetic Biosciences, Inc. (XBIO) | United States | $0.006B | |
| Processa Pharmaceuticals, Inc. (PCSA) | United States | $0.005B | |
| Pulmatrix, Inc. (PULM) | United States | $0.006B | |
| AMARIN CORP PLC\UK (AMRN) | $0.005B | -247.24 | |
| Ernexa Therapeutics Inc. (ERNA) | United States | $0.006B | |
| Dermata Therapeutics, Inc. (DRMA) | United States | $0.005B | -0.62 |
| REVIVA PHARMACEUTICALS HOLDINGS, INC. (RVPH) | United States | $0.005B | |
| Enveric Biosciences, Inc. (ENVB) | United States | $0.007B | -0.63 |
| Cadrenal Therapeutics, Inc. (CVKD) | United States | $0.004B | -0.90 |
| Bolt Biotherapeutics, Inc. (BOLT) | United States | $0.007B | -0.26 |